Physician profile
Nisha Thomas
NPI 1700216504
$6,843.94
in general payments reported to CMS, 2019-2025
26 companies · $1,924 in 2025
The $1,924 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $797 · 2022: $1,265 · 2023: $1,380 · 2024: $1,477 · 2025: $1,924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,781.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,295.58 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,115.38 | 2021-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $745.39 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $705.01 | 2021-2025 | Ozempic, Rybelsus, Tresiba |
| Abbvie INC. | $603.08 | 2022-2025 | |
| Amarin Pharma, INC. | $435.36 | 2021-2023 | |
| Glaxosmithkline, LLC. | $331.84 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $254.63 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $176.10 | 2022-2024 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $167.33 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.22 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Exact Sciences Corporation | $158.74 | 2024-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $122.81 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.74 | 2023-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $87.59 | 2022-2025 | Veozah |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $87.26 | 2022 | |
| Sumitomo Pharma America, INC. | $50.92 | 2024 | Gemtesa |
| Nestle Healthcare Nutrition INC. | $41.75 | 2021 | |
| Esperion Therapeutics, INC. | $35.79 | 2023 | Nexletol |
| Xeris Pharmaceuticals, INC. | $34.80 | 2024-2025 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $33.42 | 2022 | |
| Scilex Pharmaceuticals INC. | $29.77 | 2024 | |
| Abbott Laboratories | $18.11 | 2023 | Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $16.08 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.12 | 2024 | Zoryve |
| Phadia US INC. | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nisha Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.